Asset Details
Do you wish to reserve the book?
Cabazitaxel—the taxane of choice in the new mCRPC landscape?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cabazitaxel—the taxane of choice in the new mCRPC landscape?
Do you wish to request the book?
Cabazitaxel—the taxane of choice in the new mCRPC landscape?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cabazitaxel—the taxane of choice in the new mCRPC landscape?
2014
Overview
Cabazitaxel, a next-generation taxane, retains its efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress on new androgen receptor (AR)-targeted agents such as abiraterone acetate or enzalutamide. These findings are reinforced by
in vitro
preclinical data confirming cross-resistance between abiraterone and enzalutamide, but not between cabazitaxel and AR-targeted agents.
Publisher
Nature Publishing Group UK,Nature Publishing Group
